Does Ginkgo biloba reduce the risk of cardiovascular events?

ABSTRACT:

Background

Cardiovascular disease (CVD) was a preplanned secondary outcome of the Ginkgo Evaluation of Memory Study. The trial previously reported that Ginkgo biloba had no effect on the primary outcome, incident dementia.

Methods and results

The double-blind trial randomly assigned 3069 participants over 75 years of age to 120 mg of G biloba EGb 761 twice daily or placebo. Mean follow-up was 6.1 years. The identification and classification of CVD was based on methods used in the Cardiovascular Health Study. Differences in time to event between G biloba and placebo were evaluated using Cox proportional hazards regression adjusted for age and sex. There were 355 deaths in the study, 87 due to coronary heart disease with no differences between G biloba and placebo. There were

SUBMITTER: Kuller LH 

PROVIDER: S-EPMC2858335 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature